Indian J Pharm Close
 

Table 16: Question 4 (vi) Given the BOLERO‑ 2 trial data, can the combination of everolimus and exemestane be considered as standard treatment option in patients with HR +ve/Her2 – ve breast cancer that has progressed on a previous AI in the post‑menopausal setting?

Table 16: Question 4 (vi) Given the BOLERO‑ 2 trial data, can the combination of everolimus and exemestane be considered as standard treatment option in patients with HR +ve/Her2 – ve breast cancer that has progressed on a previous AI in the post‑menopausal setting?